Fineline Cube

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

China’s National Medical Products Administration (NMPA), in coordination with six other regulatory bodies, has jointly...

Policy / Regulatory

China’s NHC Unveils 16-Point Pediatric Medicines Reform to Strengthen Supply Security and Clinical Access

Fineline Cube May 8, 2026

China’s National Health Commission (NHC) released comprehensive “Implementation Opinions on Reforming and Improving the Supply...

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026

Bayer AG (ETR: BAYN) and Perfuse Therapeutics Inc. announced on May 6, 2026, a definitive...

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Fineline Cube May 7, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) released its first-quarter 2026 financial results on May 6, 2026,...

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Fineline Cube May 7, 2026

Novo Nordisk A/S (NYSE: NVO) released its first-quarter 2026 financial results on May 6, 2026,...

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Fineline Cube May 7, 2026

Eli Lilly and Company (NYSE: LLY) announced on May 6, 2026, an additional USD 4.5...

Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026

China’s National Health Commission (NHC) announced a significant expansion of the country’s pediatric healthcare infrastructure,...

Others

Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline

Fineline Cube May 7, 2026

Kexing Pharmaceutical (SHA: 688136), an innovative biopharmaceutical company with an international footprint, released its prospectus...

Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026

Chia Tai Tianqing Pharmaceutical Group, a wholly owned subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177),...

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Fineline Cube May 7, 2026

Sino Biopharmaceutical Ltd. (HKG: 1177) announced the first patient enrollment in a Phase III regulatory...

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Fineline Cube May 7, 2026

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene, Ltd., reported...

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026

Cutia Therapeutics (HKG: 2487), a dermatology-focused specialty pharmaceutical company, announced that China’s National Medical Products...

Company Drug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Fineline Cube May 7, 2026

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical...

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026

Amoytop Biotech Co. Ltd. (SHA: 688278) released its prospectus for convertible bond issuance to unspecified...

Company Drug

Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia

Fineline Cube May 7, 2026

Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that China’s National Medical Products Administration...

Company Drug

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China

Fineline Cube May 7, 2026

Amgen Inc. (NASDAQ: AMGN) announced that China’s National Medical Products Administration (NMPA) has granted marketing...

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026

China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Biosunpharma Co., Ltd. for...

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that its US partner Dianthus Therapeutics (NASDAQ:...

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Fineline Cube May 6, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) announced it has received clinical trial approval from China’s...

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026

Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on kidney disease therapeutics, has filed its prospectus...

Fineline Cube

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

China’s NHC Unveils 16-Point Pediatric Medicines Reform to Strengthen Supply Security and Clinical Access

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

You Missed

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership